GSK spins out corporate VC fund focused on bioelectronic tech

GSK has spun out its corporate venture capital unit, Action Potential Venture Capital (APVC), which focuses on investing in bioelectronic startups. This marks the second time GSK has separated from a corporate venture unit, following the spin-out of its biopharma-focused fund, SR One, in 2020. A new entity, Synapse Fund, backed by SR One and others, will now manage these investments.